Meeting
2020 Gastrointestinal Cancers Symposium
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
Authors
Mohammed Al-Jumayli
Kansas University Cancer Center, Kansas, KS
Mohammed Al-Jumayli , Hannah Hildebrand , Saqib Abbasi , Anup Kasi , Anwaar Saeed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 533)
Abstract #
533
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Comparative efficacy of second-line treatments for advanced hepatocellular carcinoma: A network meta-analysis.
First Author: Neehar Parikh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
First Author: Jamie Grossman
Poster
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
First Author: M. Naomi Horiba
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Mathias Earl Palmer